JP2025516315A - 置換イミダゾピリジンおよびイミダゾピリミジン、ならびに網膜変性を処置、改善、および／または予防するためのその使用 - Google Patents

置換イミダゾピリジンおよびイミダゾピリミジン、ならびに網膜変性を処置、改善、および／または予防するためのその使用 Download PDF

Info

Publication number
JP2025516315A
JP2025516315A JP2024564932A JP2024564932A JP2025516315A JP 2025516315 A JP2025516315 A JP 2025516315A JP 2024564932 A JP2024564932 A JP 2024564932A JP 2024564932 A JP2024564932 A JP 2024564932A JP 2025516315 A JP2025516315 A JP 2025516315A
Authority
JP
Japan
Prior art keywords
compound
subject
compounds
cells
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024564932A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025516315A5 (cg-RX-API-DMAC10.html
Inventor
マーク フィールズ
デントン ホイヤー
プリオーレ ルーシアン デル
ヒューイ カイ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of JP2025516315A publication Critical patent/JP2025516315A/ja
Publication of JP2025516315A5 publication Critical patent/JP2025516315A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2024564932A 2022-05-04 2023-05-04 置換イミダゾピリジンおよびイミダゾピリミジン、ならびに網膜変性を処置、改善、および／または予防するためのその使用 Pending JP2025516315A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263338264P 2022-05-04 2022-05-04
US63/338,264 2022-05-04
US202263411405P 2022-09-29 2022-09-29
US63/411,405 2022-09-29
PCT/US2023/020978 WO2023215465A1 (en) 2022-05-04 2023-05-04 Substituted imidazopyridines and imidazopyrimidines, and use of same for treating, ameliorating, and/or preventing retinal degeneration

Publications (2)

Publication Number Publication Date
JP2025516315A true JP2025516315A (ja) 2025-05-27
JP2025516315A5 JP2025516315A5 (cg-RX-API-DMAC10.html) 2026-05-13

Family

ID=88647025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024564932A Pending JP2025516315A (ja) 2022-05-04 2023-05-04 置換イミダゾピリジンおよびイミダゾピリミジン、ならびに網膜変性を処置、改善、および／または予防するためのその使用

Country Status (7)

Country Link
US (1) US20250288588A1 (cg-RX-API-DMAC10.html)
EP (1) EP4519268A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025516315A (cg-RX-API-DMAC10.html)
CN (1) CN119487033A (cg-RX-API-DMAC10.html)
AU (1) AU2023265523A1 (cg-RX-API-DMAC10.html)
CA (1) CA3251997A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023215465A1 (cg-RX-API-DMAC10.html)

Also Published As

Publication number Publication date
EP4519268A1 (en) 2025-03-12
WO2023215465A1 (en) 2023-11-09
US20250288588A1 (en) 2025-09-18
CA3251997A1 (en) 2023-11-09
AU2023265523A1 (en) 2024-11-21
CN119487033A (zh) 2025-02-18

Similar Documents

Publication Publication Date Title
JP6602802B2 (ja) Ｓｓａｏの置換３−ハロアリルアミン阻害剤およびその使用
ES2585262T3 (es) Compuestos heterocíclicos de hexahidropiran[3,4-d][1,3]tiazin-2-amina sustituidos como inhibidores de PPA, BACE1 y BACE2
US11858910B2 (en) Pyridinylmethylenepiperidine derivatives and uses thereof
IL139862A (en) History of thiazolidine or pyroladine as effects of dipheptidyl peptides IV and pharmaceutical preparations containing them
US11897887B2 (en) sGC stimulators
CN114286816B (zh) 赖氨酰氧化酶的二氟卤代烯丙胺砜衍生物抑制剂、其制备方法和用途
CN115768419A (zh) 用于色满卡林前药治疗的改进方法和组合物
CA3159771A1 (en) Controlled-delivery cromakalim prodrugs
EP2271334B1 (en) Methods of treating fibrotic disorders
US20230017597A1 (en) 8-substituted styryl xanthine derivatives and uses thereof
US20250222115A1 (en) Drug Conjugates of Sugar Derivatives and Uses Thereof as Senolytic Agents
CA3005527C (fr) Mirabegron pour le traitement de maladies retiniennes
US20250288588A1 (en) Substituted imidazopyridines and imidazopyrimidines, and use of same for treating, ameliorating, and/or preventing retinal degeneration
WO2025199211A1 (en) Imidazopyridines and imidazopyrimidines, and methods of using same
WO2023006993A1 (en) Fused amino pyridine or pyrimidine derivatives for the treatment of congenital central hypoventilation syndrome
CN114945577B (zh) 大环内酯化合物及其治疗慢性呼吸道疾病的用途
WO2024044813A1 (en) Novel selective inhibitors of lysyl oxidases
WO2009110526A1 (ja) ３’，５－ジ－２－プロペニル－（１，１’－ビフェニル）－２，４’－ジオールを有効成分として含有する視神経障害の予防又は治療剤
CN118591529A (zh) 氘代rock抑制剂、药物组合物和治疗应用
KR20170095850A (ko) 각막 상피 장애 치료제
TW202602459A (zh) Gpx4抑制劑與抗衰老化合物及其用途
CN121270631A (zh) 含一氧化氮供体的化合物
WO2019136466A1 (en) Compounds and methods for treating or preventing anterior segment ocular disorders and/or retinal degenerations
HK1193349A1 (zh) 特徵在於是将透明质酸及黄素腺嘌呤二核苷酸组合而成的角膜上皮细胞死亡的抑制剂
RU2007112885A (ru) Способ лечения глазных заболеваний

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260430

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260430

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260721

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20260810